In Kaposi’s sarcoma (KS), i.v. injected BM-MSCs inhibit KS tumour growth in vivo by inhibiting Akt activation in a dose-dependent manner; interestingly, this phenomenon was only observed for primary tumour cells but not tumour cell lines [56]. Here, AKT1 is linked to Kaposi's sarcoma.